The biodistribution and pharmacokinetics of [177Lu]Lu-DOTA-hG250 were studied ex vivo, after dissection of Renca-CAIX and CT26-CAIX tumor-bearing mice at 1, 3, and 7 days post-treatment (Figure 3A, Table S4). Here, CA9 is linked to neoplasm.